Fig. 5
Metabolic differences of mice in different groups. A–D Volcano plot (A, B) and hierarchical clustering heatmap (C, D) show differential accumulation of metabolites in the control and PTB groups. C POS Mode: S4940793: Sulukast; S29213982: (3β,4β,5α,15α,16β,25s)-4,5,8,15,16,26-hexahydroxycholestan-3-yl 2-o-methyl-β-d-xylopyranoside; S8184341: N-acetyldeferoxamine; S113385087: (2β,3β,5β,22r)-2,20,22-trihydroxy-6-oxocholesta-7,14-dien-3-yl β-d-glucopyranoside; S21171849: 1-o-[(1,3,24,28-tetrahydroxy-4,14-dimethyl-22,28-epoxy-9,19-cycloergostan-4-yl)carbonyl]hexopyranose; S13095592: Timosaponin aiii; S10128567: Actodigin; S10128391: cyclic-3,20-bis(1,2-ethanediyl acetal)-11α-(acetyloxy)-5α,6α-epoxypregnane-3,20-dione; S24822065: prostaglandin F2α serinol amide; S24344: hydrocortisone butyrate (jp15/usp); S388633: Z-Gly-Pro; S64280: promolate; S390806: cinnamodial; S389284: 3-(4-hydroxy-3,5-diiodophenyl)lactic acid; S86330: 3-bromo-1-thiolane-1,1-dione; S2279: betaxolol; S4572761: (2e)-3-(4-hydroxyphenyl)-n-[2-(1h-indol-3-yl)ethyl]acrylamide/Nb-p-coumaroyltryptamine; S38173: medroxalol; S91814: (−)-lobeline; S4763: propafenone. D NEG mode: S7850857: fenpyroximate; S391405: N-acetylleucylleucine; S24766525: 1-[(9z)-hexadecenoyl]-sn-glycero-3-phosphocholine; S24766524: lysophosphatidylcholine 14:1(9z)/0:0; S388756: {[(3α,7α,8ξ,10ξ,12α,13ξ,17ξ,20ξ)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino}methyl hydrogen sulfate; S66155: ergocornine; S25104194: mapracorat; S29213982: (3β,4β,5α,15α,16β,25s)-4,5,8,15,16,26-hexahydroxycholestan-3-yl 2-o-methyl-β-d-xylopyranoside; MReference-6510: cannabigerolic acid; S6372: chlorfenethol; S61936: arbekacin; S8034790: 3,10-dihydroxydecanoic acid; S106391: 2-amino-2-deoxy-4-o-β-d-galactopyranosyl-d-glucose; MReference-1264: pyruvic acid; S8376347: (−)-acutumine; S119692: cystathionine ketamine; S23215413: (9z,12z,15z)-n-[2-(3,4-dihydroxyphenyl)ethyl]-9,12,15-octadecatrienamide; S65090: icotidine; S8409: N-butyl lactate